Newron Pharmaceuticals S.p.a.

Dac S.r.l.

Vicuron Pharmaceuticals Inc.

Istituto Europeo Di Oncologia S.r.l.

Florian Thaler

Patricia Salvati

Mario Varasi

Carla Caccia

Saverio Minucci

Ciro Mercurio

Laura Faravelli

Mauro Napoletano

Alessandra Restivo

Luca Benatti

Cibele Sabido-David

Ermanno Moriggi

Elena Barbanti

Cibele Maria Sabido David

Agnese Abate

Stefania Gagliardi

Luca Francesco Raveglia

Emanuela Izzo

Ruggero Fariello

Giacomo Carenzi

Sara Maestroni

Claudia Besana

Roberto Pellicciari

Enrico Selva

Paola Vianello

Raffaella Amici

Antonello Mai

Elena Colombo

Daniele Losi

Marco Ballarini

Orietta Veneroni

Gilles Pain

Silvio Massa

Giuseppe Meroni

Gaetano Gargiulo

Pier Giuseppe Pelicci

Andrea Colombo

Paolo Trifiro′

Paolo Trifiro'

Maria Carmela Fulco

Petra Karin Kaltofen

Laura Girola

The present invention relates to cyclopropyl derivatives of general formula (I), wherein A, R, and Rare as defined in the specification. The present application also relates to pharmaceutical compositions containing such compounds and to their use in therapy. 

Cycloproplyamine derivatives useful as inhibitors of histone demethylases KDM1A

This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: the dotted line is an optional additional bond; n is zero or an integer from 1 to 4; Ris hydrogen; C-Calkyl, optionally substituted by cycloalkyl, aryl or by heteroaryl; (CO)R; (SO)R; cycloalkyl; aryl; or heteroaryl; Ris C-Calkyl, optionally substituted by aryl or by heteroaryl; aryl; heteroaryl; or (CO)R; X is CH, oxygen or NR; Y is a bond, CHRor NR; Z is oxygen, CRRor C&#x2550;R; and R, R, R, R, R, R, R, Rand Rare as further defined in the specification; and pharmaceutical acceptable salts thereof. 

Spirocyclic derivatives as histone deacetylase inhibitors

This invention is related to new histone deacetylase inhibitors according to the general formula (I), wherein: m and n are independently zero or an integer from 1 to 4; p is zero or an integer from 1 to 3, with the proviso that when p is zero, n and m cannot be both 1; R is hydrogen; C-Calkyl, optionally substituted by C-Ccycloalkyl, C-Caryl or hetero(C-C)aryl; (CO)R; (SO)R; C-Ccycloalkyl; C-Caryl; or hetero(C-C)aryl; Ris halogen, C-Calkyl, C-Chaloalkyl, C-Calkoxy, C-Chaloalkoxy; Y is CHor NR; Z is C&#x2550;R; and R, R, R, and Rare as further defined in the specification; and pharmaceutical acceptable salts thereof. 

Methods of using certain &#x3b1;-aminoamide derivatives in the treatment of RLS and addictive disorders, The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

Alpha-aminoamide derivatives useful in the treatment of addictive disorders

2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.

2-phenylethylamino derivatives as calcium and/or sodium channel modulators

The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.

&#x3b1;-Aminoamide derivatives useful in the treatment of restless legs syndrome

New histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH, CH&#x2014;NRR, NRor oxygen, X is CH or nitrogen, Y is a bond, CH, oxygen or NR, Z is CH or nitrogen, R, Rare, independently, hydrogen, halogen, C-Calkyl or C-Chaloalkyl, R, Rare, independently, hydrogen or C-Calkyl, and R, R, Rand Rare as further defined in the specification.

Class of histone deacetylase inhibitors

A method for treating pain, migraine, inflammation, gastrointestinal tract disorders, disorders of the genito-urinary tract, ophthalmic diseases or obesity in a subject, the method including administering to the subject an effective amount of a compound of a general formula, specific examples of which include 3-(4-Butyloxy-benzylamino)-pyrrolidin-2-one, 3-[4-(4-trifluorobutyloxy)-benzylamino]-pyrrolidin-2-one, 3-(4-Pentyloxy-benzylamino)-pyrrolidin-2-one, 3-[4-(5-trifluoropentyloxy)-benzylamino]-pyrrolidin-2-one, and 3-(4-Phenylethyl-benzylamino)-pyrrolidin-2-one.

3-aminopyrrolidone derivatives

3-aminopyrrolidone compounds and pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases.

2-Phenylethylamino substituted carboxamide derivatives of formula (I); wherein J, W, R, R, R, R, and Rhave the meanings as defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urology, and gastrointestinal diseases where the above mechanisms have been described as playing a pathological role, are described. 

This invention is related to hydroxylamino derivatives of the general formula (I) wherein n is 0, 1 or 2; Rand R, independently of each other, are H, OH or OCH; Ris H or CH; Ris H, C-Cstraight or branched alkyl or, together with R, forms a five to seven-membered carbocyclic ring; and Rand R, independently of each other, are H or C-Cstraight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing said compounds and to pharmaceutical compositions containing them. 

Hydroxylamine derivatives

Methods of using certain &#x3b1;-aminoamide derivatives to treat lower urinary tract disorders. The therapeutic agents of the invention are able to reduce or even stop the lower urinary tract disorders substantially without side effects.

Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders

This invention is related to compounds and use of N-Acyl-N'-benzyl-alkylendiamino derivatives of the following general formula (I), wherein A is a straight or branched C-Calkyl chain; X is a methylene, oxygen, sulphur or a NRgroup; Ris a straight or branched C-Calkyl or C-Calkenylene or C-Calkynylene chain, optionally substituted with CF, phenyl, phenoxy or naphthyl, the aromatic rings optionally substituted by one or more C-Calkyl, halogens, trifluoromethyl, hydroxy or C-Calkoxy groups; R, Rare independently hydrogen, a C-Calkyl chain, halogen, trifluoromethyl, hydroxy or C-Calkoxy groups; R, Rare independently hydrogen or C-Calkyl; Ris a hydrogen or a straight or branched C-Calkyl or linked to Rcan form a five to seven membered lactam; Ris hydrogen or C-Calkyl; and the pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role 

N-acyl-N'-benzyl-alkylendiamino derivatives

Growing community of inventors

Gerenzano, Italy

Florian Thaler